Table 5.
Characteristics of patients with and without immune checkpoint inhibitor including therapy after lenvatinib treatment
| With ICI including therapy | Without ICI including therapy | P‐value | |
|---|---|---|---|
| N | 24 | 64 | |
| Age (years) | 69.6 ± 9.7 | 70.7 ± 9.4 | NS |
| Sex (male/female) | 21/3 | 50/14 | NS |
| BMI (kg/m2) | 23.7 ± 3.6 | 23.9 ± 3.9 | NS |
| Etiology (viral/non‐viral) | 12/12 | 32/32 | NS |
| Complication: hypertension | 14 (58%) | 45 (70%) | NS |
| Complication: diabetes | 10 (42%) | 18 (28%) | NS |
| APRI | 1.05 ± 0.97 | 1.17 ± 1.04 | 0.031 |
| FIB‐4 index | 4.97 ± 0.27 | 4.92 ± 0.32 | NS |
| Child–Pugh score | 5.71 ± 1.12 | 5.84 ± 1.20 | <0.01 |
| ALBI score | −2.40 ± 0.56 | −2.39 ± 0.50 | NS |
| TNM stage (2/3/4) | 7/7/10 | 10/25/29 | NS |
| Within Up‐to‐7 criteria | 10 (42%) | 28 (44%) | NS |
| Treatment duration (days) (median) | 180 (4–870) | 105 (3–922) | NS |
| Change therapy by PD | 18 (75%) | 35 (55%) | NS |
| ORR | 8 (33%) | 15 (24%) | NS |
| DCR | 17 (71%) | 47 (73%) | NS |
| Change therapy by AE | 5 (22%) | 31 (48%) | 0.019 |
| Grade ≥ 2 AEs | 13 (54%) | 47 (73%) | NS |
| AE, HFS | 2 (8%) | 19 (30%) | 0.018 |
| AE, proteinuria | 4 (17%) | 10 (16%) | NS |
| AE, hypertension | 6 (26%) | 13 (20%) | NS |
| AE, fatigue | 2 (9%) | 10 (16%) | NS |
| AE, appetite loss | 0 (0%) | 6 (9%) | 0.024 |
| Other therapy, TACE | 1 (4%) | 32 (50%) | <0.01 |
| Radiation therapy | 1 (4%) | 11 (17%) | 0.04 |
| Second line TKIs | 4 (17%) | 31 (48%) | <0.01 |
| Operation | 1 (4%) | 1 (2%) | NS |
| Radiofrequency ablation | 0 (0%) | 3 (5%) | NS |
Values are n, n (%), or mean ± SD, unless otherwise specified.
AE, adverse effect; APRI, AST‐to‐platelet ratio index; BMI, body mass index; DCR, disease control rate; FIB‐4, fibrosis‐4; ICI, immune checkpoint inhibitor; NS, not significant; ORR, overall response rate; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TNM, tumor‐node‐metastasis.